Apovincaminic acid hydrochloride salt, the primary active metabolite of Vinpocetine (VP), is orally active and has the ability to penetrate the brain. It demonstrates a neuroprotective mechanism of action [1][2].

Apovincaminic acid (10 mg/kg; i.p. twice daily for 4 days) effectively attenuates the behavioral deficits, and significantly decreases lesion size and the region of microglia activation[1].Apovincaminic acid (10 mg/kg; p.o.) is absorbed 50% of the dose comparing with i.v. administration in rats[2]. Animal Model: Male Harlan‐Wistar rats (300-400 g) are injected NMDA[1]